Coy update RNS23 Feb 2017 07:15
Commenting on the results, CEO Marcelo Bravo said:
"Oxford Pharmascience is very pleased with these exploratory, interim PK study results, which demonstrate that the technolology modifications can not only make OXPzero™ Ibuprofen bioequivalent to ibuprofen free acid (NurofenTM), but also potentially faster acting. Achieving a product that is bioequivalent to reference is highly important to OXP as the regulatory pathway to gaining product approval generally becomes faster, simpler and therefore less costly for bioequivalent products. The potential to accelerate speed of action or to extend the duration of effect is expected to further differentiate prospective OXPzeroTM products.
"These results indicate a strong position with an OXPzeroTM Ibuprofen asset that can be made bioequivalent, completely taste masked and either faster acting or having an extended duration of effect compared to the reference product."